Nut Recall Map Shows Six States With New Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Retailer Meijer is recalling packages of Frederik's brand Dark Chocolate Almonds this week because they could potentially contain cashews, which are not disclosed on the packaging.
Newsweek reached out to the company via email Tuesday night for comment.
Why It Matters
Numerous recalls have been initiated in 2025 due to the potential of damaged products, foodborne illness, contamination and undeclared food allergens.
Millions of Americans experience food sensitivities or allergies every year. According to the Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts.
The FDA also warns that people with an allergy or severe sensitivity to cashew nuts potentially "run the risk of a serious or life-threatening allergic reaction if they consume the product."
What To Know
In the alert, the agency says that the recall includes the dark chocolate-covered almonds sold in stand-up pouches in Meijer stores, with sell by dates of May 7, 2026, and May 28, 2026.
Additional 8-count 1.5-ounce multi-pack boxes with a sell by date of May 5, 2026, are also part of the recall, the FDA says.
The almonds were sold in the following states: Michigan, Indiana, Illinois, Ohio, Kentucky and Wisconsin, according to the agency.
The FDA alert also shows a chart listing the affected products, with corresponding UPC code numbers. There have been no reported illnesses related to the recall as of Monday, per the agency.
What People Are Saying
The FDA in the alert, in part, regarding the company: "About Meijer: Meijer is a privately owned, family-operated retailer that serves customers at more than 500 supercenters, grocery stores, neighborhood markets, and express locations throughout the Midwest."
Continuing: "As the pioneer of the one-stop shopping concept, more than 70,000 Meijer team members work hard to deliver a friendly, seamless in-store and online shopping experience featuring an assortment of fresh foods, high-quality apparel, household essentials, and health and wellness products and services. Meijer is consistently recognized as a Great Place to Work and annually donates at least 6 percent of its profit to strengthen its communities. Additional information on the company can be found by visiting newsroom.meijer.comExternal Link Disclaimer."
What Happens Next
Customers who have purchased the recalled chocolate-covered nuts are urged to return the product to a Meijer store for a refund, the FDA says.
Those with additional questions may contact Meijer at 800-543-3704 from 7 a.m. to 1 a.m. ET every day. "Customers with questions or concerns about their health are encouraged to contact their primary care provider," the alert also notes.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2 Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatment SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort (Cohort 3) of its ongoing Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT). "We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs." Patients in Cohort 3 will receive up to four fixed administered doses of [212Pb]VMT-α-NET at 6 mCi every eight weeks if they weigh more than 60kg (133lb), or 100μCi/kg of body weight if they weigh less than or equal to 60kg. Observations of dose limiting toxicities (DLTs) in up to eight patients within 42 days of the first treatment cycle will be used to assess whether this cohort of patients have received maximum tolerated dose (MTD) or maximum feasible dose (MFD). Once a safety monitoring committee (SMC) has reviewed the data from these initial patients, it may recommend exploring alternative dosing and/or recruit more patients into Cohort 3. Perspective is notifying sites that Cohort 3 is now open for recruitment. Patients currently being evaluated for entry into the study will enroll into Cohort 3 if they qualify. Pending feedback from sites on operationalizing enrollment into Cohort 3, an update on pace of recruitment will be provided in due course. About [212Pb]VMT-α-NETPerspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study ( identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Perspective Therapeutics, Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's belief that it is on track to submit further clinical updates to scientific congresses in 2H 2025 and the planned content of such updates; the Company's ability to explore a higher dose level of VMT-α-NET; the Company's commitment to engage with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of its proprietary RPTs; the Company's expectation that patients currently being evaluated for entry into its VMT-α-NET study will enroll into Cohort 3 if they qualify; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: Perspective Therapeutics IR:Annie J. Cheng, CFAir@ Russo Partners, LLCNic JohnsonPerspectiveIR@
Newsweek
an hour ago
- Newsweek
The Key to Better Sleep Is in Your Gut, Says Gastroenterologist
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Around 25 million U.S. adults suffer from insomnia. At the same time, more than 3.9 million Americans are taking probiotics, usually for gut health, according to the American Gastroenterological Association (AGA). And gut health could be the key to better sleep. A study published in the journal Engineering examined a specific probiotic strain called Lactobacillus helveticus CCFM1320. This probiotic produces a compound known as SAM (S-adenosylmethionine), which helps regulate the body's internal clock and supports the production of melatonin, a hormone that promotes sleep. The researchers found that this probiotic could significantly improve sleep quality. The Gut as a Second Brain Neuroscientist Dr. Chelsie Rohrscheib, the head of sleep at Wesper, a national home sleep disorder diagnostics company, told Newsweek: "The gut essentially acts as a secondary nervous system and creates and releases many crucial neurotransmitters, such as serotonin, which also help to regulate nervous system activity. "This allows for two-way communication between the gut and the brain, called the gut-brain axis. Healthy gut microbes are essential to keeping the gut healthy and functioning, and there is ample evidence that gut microbiota dysregulation can negatively impact the activity of the gut-brain axis. Because the brain is highly sensitive, this can lead to poor sleep quality." Stock image of a woman taking pills from her nightstand before bed. Stock image of a woman taking pills from her nightstand before bed. Liudmila Chernetska/iStock / Getty Images Plus Is CCFM1320 a Game-Changing Strain? To test the effectiveness of CCFM1320 in humans, scientists from Jiangnan University conducted a four-week study with 60 volunteers who experienced sleep difficulties. Participants were divided into two groups: one received the probiotic, while the other took a placebo. Results showed that those who consumed the probiotic had better sleep scores, lower levels of the stress hormone cortisol, and a healthier balance of gut bacteria. Additionally, the probiotic boosted the expression of genes involved in producing and utilizing SAM, a key factor in sleep and overall health. Strain-Specific Benefits Dr. Michel Bass, a board-certified gastroenterologist and the Founding Medical Director at Oshi Health in Philadelphia, Pennsylvania, emphasized the importance of strain specificity: "Not all probiotics are created equal. This study identified CCFM1320 as uniquely beneficial for sleep quality. This isn't a generic 'take-any-probiotic' situation—it's about strain-level specificity," Bass told Newsweek. "That's where a lot of public messaging needs to evolve. Just like different medications target different conditions, different strains do different things. And this one appears to enhance melatonin synthesis via SAM methylation—a novel pathway." Probiotic Supplements vs. Fermented Foods Stock image of an assortment of fresh vegetables and meats. Stock image of an assortment of fresh vegetables and meats. esilzengin/iStock / Getty Images Plus While fermented foods like yogurt, kimchi, and kefir are beneficial for general gut health, Bass explained that they may not provide targeted probiotic strains at therapeutic levels. "If someone wants to improve things like sleep quality or reduce stress hormones like cortisol, a strong, well-researched supplement—especially one with proven strains like CCFM1320—is usually more effective," he said. "That said, eating fermented foods is still a great daily habit and can complement targeted probiotic supplements." Jason Eastty, owner of Healthspan Longevity in Westborough, Massachusetts, and a nutrition specialist, added that overall good nutrition can combat poor sleep. "Having a nutrient deficiency—like low iron, magnesium, or vitamin D—can throw off your gut microbial balance, leading to poor sleep. Clinical trials have shown that correcting these deficiencies helps microbial diversity and improves sleep efficiency," Eastty said. He also emphasized that a whole-foods diet rich in fiber—from fruits, vegetables, legumes, nuts, seeds, and whole grains—is essential to feeding the "good" bacteria in your gut.
Miami Herald
2 hours ago
- Miami Herald
Fed study blasts few healthcare options in top U.S. tourism states
Romantic getaways. Family memories. Great escapes. We Americans love a good vacation. Don't miss the move: Subscribe to TheStreet's free daily newsletter You might be one of the millions lured this – and every – summer by a bold oceanfront, a lakeside fire pit or leafy mountain paths found in these popular tourism states. Related: Major health care company files for bankruptcy to sell assets Or maybe other seasonal adventures like world-class skiing, lush spring gardens or the simply fabulous foliage each autumn draw you and yours to these renowned venues any time of year. 'Cause there's also a ton of history, culture and sports to explore plus delicious local chow for the foodies. But beyond the cheery facades that welcome visitors are sad and scary realities that full-time residents face regarding year-round healthcare access in their rural communities. A new study by the Federal Reserve Bank of Boston spells out the first-hand accounts of mothers, children, elders and others challenged by distance, income, resources and other economic problems to receive healthcare that so many fellow Americans take for granted. The solutions don't seem to be short-term, straining hopes and accelerating chronic, life-threatening medical crises."Yep. It's a great place to visit but you wouldn't want to live here." Visitors to these states have heard this refrain from locals for decades, all the way back to the last century. Proximity to health care is an increasing concern in rural communities across America. As a result, patient care suffers. So do patients. Greater distances from primary care providers, community hospitals and trauma centers are linked to higher rates of fatal accidents, fatal heart attacks and infant mortality, according to Federal Reserve Bank of Boston senior policy analyst Riley Sullivan. Rural healthcare facilities are finding it more difficult to attract the skilled workforce to fill jobs at every level of skill. Reasons include lack of affordable or available housing and high costs of living magnified by the many, many miles from larger towns and bigger cities. Plus healthcare providers across America maintain that inadequate insurance, Medicaid or Medicare reimbursement rates are leading to major losses at private, public and not-for-profit facilities. Related: Major bankrupt healthcare provider closes distressed hospitals Overall, U.S. hospitals are finding that they have no choice but to cut services due to these acute financial challenges. Some even close because all options have simply run out, leaving their communities in medical deserts facing life-or-death choices 24-7. Boston Fed principal economist and policy advisor Mary Burke, who studies regional labor force participation rates, said all these issues add up to big strains on healthcare systems in Maine, New Hampshire and Vermont. Sullivan's study showed: Northern Light Health, Maine's second-largest health care system, lost a staggering $156 million in 2024. Northern Light Inland Hospital in Waterville (known for its ski resorts) closed earlier this year. In New Hampshire, Catholic Medical Center in Manchester reported monthly losses ranging from "$2 - $3 million," before it was sold in February Vermont, a state-mandated though disputed analysis found that its hospitals will need to find between $700 million and $2.4 billion to break even by 2028. "I think that when you look around the country in rural areas and you find thriving health care systems or hospitals, what you see are thriving communities, where economic development is strong," said Dr. Sunil Eappen, CEO of The University of Vermont Health Network. Economic development is the key to reversing these trends in Vermont and its two northern neighbors. Tourism dollars, though in the millions, just aren't enough. Eappen, also a member of the Boston Fed's Board of Directors, said potential catalysts – including improved infrastructure and more housing – would help stop the bleeding of healthcare access. But ultimately, it all comes down to one thing. "We need another 100-150,000 young people to move in who are working and paying into a commercial insurance population," Eappen said. "We need more people to move in." Related: Major hospital chain owner files for Chapter 11 bankruptcy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
